AstraZeneca Might Struggle to Expand Patient Population for Rare Disease Drug -- Market Talk

Dow Jones03-31

0959 GMT - AstraZeneca's efzimfotase alfa experimental drug for the rare metabolic condition hypophosphatasia missed the key objective in a late-stage trial with adult patients that was key to expanding the patient population, Bank of America analysts say in a research note. The U.K. drugmaker reported mixed results from three late-stage studies of the treatment, with two pediatric studies hitting their objectives and one in adults missing it, Bank of America says. The drug was being studied as a follow-on to the company's Strensiq treatment and the study in adults was the easiest way to secure a expanded population, the analysts say. AstraZeneca plans to share the data with regulators and still sees the lower end of its peak sales target of $3 billion to $5 billion as potentially achievable, the bank says. Shares rise 0.2%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 31, 2026 05:59 ET (09:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment